Dopaminergic System Antagonist - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “Dopaminergic system Antagonist - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Dopaminergic system Antagonist development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the ReportProvides a snapshot of the therapeutics pipeline activity for Dopaminergic system Antagonist Features the Dopaminergic system Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Dopaminergic system Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Dopaminergic system Antagonist
Reasons to BuyEstablish a comprehensive understanding of the current pipeline scenario across Dopaminergic system Antagonist to formulate effective R&D strategies Assess challenges and opportunities that influence Dopaminergic system Antagonist research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Dopaminergic system Antagonist Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Dopaminergic system Antagonist to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
Key Topics Covered
1. Report Introduction
2. Dopaminergic system Antagonist - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Dopaminergic system Antagonist
4. Comparative Analysis
5. Dopaminergic system Antagonist Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Dopaminergic system Antagonist Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies FeaturedAlkermes PLC Delpor Fabre-Kramer Pharmaceuticals Eli Lilly Schering-Plough Otsuka Pharmaceutical Acacia Pharma Zysis Altos Therapeutics Takeda Oncology Aequus Pharmaceuticals CMG Pharmaceutical Otsuka Pharmaceutical Zysis Aequus Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c8jplg/dopaminergic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005252/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/01/2019 08:01 AM/DISC: 02/01/2019 08:01 AM